ESTIMATED
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 0 | $1.58 | $1.58 | $1.58 |
Q2 2024 | 0 | $1.34 | $1.34 | $1.34 |
Q3 2024 | 0 | $1.54 | $1.54 | $1.54 |
NLS Pharmaceutics AG last posted its earnings results on N/A. The company reported $N/A earnings per share for the quarter, missing analysts' consensus estimates of $N/A by $0. The company had revenue of 0 for the quarter and had revenue of 0 for the year. NLS Pharmaceutics AG has generated $0 earnings per share over the last year ($-0.32 diluted earnings per share) and currently has a price-to-earnings ratio of -0.51. NLS Pharmaceutics AG has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 28th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/15/2024 | Q4 2023 | -$0.14 | $0 | $0 | 06/29/2023 | Q2 2023 | -$0.20 | $0 | $0 | 05/05/2023 | Q4 2022 | -$0.29 | $0 | 10/11/2022 | Q2 2022 | -$0.54 | $0 | 03/24/2022 | Q4 2021 | -$0.50 | $0 | 09/28/2021 | Q2 2021 | -$0.42 | $0 | 05/14/2021 | Q4 2020 | -$0.34 | $0 | 06/29/2020 | Q2 2020 | -$0.11 | $0 | 12/30/2019 | Q4 2019 | -$0.18 | $0 | 06/29/2019 | Q2 2019 | -$0.31 | $0 | 12/30/2018 | Q4 2018 | -$0.48 | $0 | 06/29/2018 | Q2 2018 | -$0.34 | $0 | 03/30/2018 | Q1 2018 | -$0.12 | $0 | 06/29/2017 | Q2 2017 | -$0.16 | $0 | 03/30/2017 | Q1 2017 | -$0.16 | $0 |
---|
A. NLS Pharmaceutics AG has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 28th, 2024 based off last year's report dates.
A. The conference call for NLS Pharmaceutics AG's latest earnings report can be listened to online.
A. The conference call transcript for NLS Pharmaceutics AG's latest earnings report can be read online.
A. NLS Pharmaceutics AG (NASDAQ:NLSP) has a recorded net income of $0. NLS Pharmaceutics AG has generated $-0.32 earnings per share over the last four quarters.
A. NLS Pharmaceutics AG (NASDAQ:NLSP) has a price-to-earnings ratio of -0.51 and price/earnings-to-growth ratio is -0.01.